EQL Pharma publishes information memorandum
NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.
EQL Pharma AB (publ) (“the Company”) today publishes an information memorandum in connection with the rights issue decided by the Company’s board of directors on the 17th of October 2018. The information memorandum is made available on the Company’s website and on Spotlight Stock Market’s, Västra Hamnen Corporate Finance AB’s and Aqurat Fondkommission AB’s respective websites. The subscription period commences on the 30th of October 2018.
The rights issue in brief
| Subscription period | October 30th until November 13th, 2018 | |
| Trading in subscription rights | October 30th until November 9th, 2018 | |
| Subscription price | SEK 6.00 per share | |
| Terms | Each existing share entitles to one (1) subscription right and six (6) subscriptions rights entitle to subscription of one (1) new share | |
| Issued amount at full subscription | Approximately SEK 24.9 million before issue costs | |
| Number of shares before the rights issue | 24,911,666 shares | |
| Number of new issued shares at full subscription | 4,151,944 shares | |
| Subscription undertakings and underwriting commitments | The Company has received subscription undertakings and underwriting commitments corresponding to 100 percent of the rights issue | |
| Share short name | EQL | |
| ISIN-codes | Common share | SE0005497732 |
| Subscription right (TR) | SE0011844166 | |
| Paid subscribed share (BTA) | SE0011844174 | |
Important information
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in EQL Pharma. Any invitation to the persons concerned to subscribe for shares in EQL Pharma will only be made through the information memorandum that the Company has now published.
This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa, or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No subscription rights, BTAs (interim shares) or shares have or will be registered under the U.S. Securities Act of 1933, as amended, (“Securities Act”), or securities legislation in any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.
This press release may contain forward-looking statements which reflect EQL Pharma’s current view on future events and financial and operational development. The words “intend”, “estimate”, “expect”, “may”, “plan”, “anticipate” or similar expressions regarding indications or prognoses of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties and the outcome could differ materially from the information set out in the forward-looking statements.
For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
This information was provided by the above contact person for publication on October 29th, 2018.
About EQL Pharma
EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets ten (10) generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (7) people and is listed on Spotlight Stock Market (AktieTorget). EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.